Brian Sozzi: McDonald’s GLP-1 defense is ‘ridiculous’ — investors unconvinced

Bullish Gator

Sozzi warns GLP-1 drugs will pressure fast-food chains; McDonald’s points to 84% of GLP-1 households still visiting, yet its stock hit a 10-year low after investor day.

Editorial companion

What stands out

Brian Sozzi dismisses McDonald’s defense that 84 percent of households on GLP-1 weight-loss drugs still visit its restaurants as "ridiculous," arguing those drugs will pose a major headwind for fast-food chains over the next decade. The clip highlights a clash between McDonald’s investor-day messaging and market reality: shares fell to a 10-year low valuation after the presentation. The back-and-forth matters because it compresses a simple story, company data versus a disruptive trend, into a single, public confrontation that investors can react to immediately.